Overall, our current observations with IKBKAP-FD exon 20 not only highlight RECTAS as a potential therapeutic agent for FD but also suggest the feasibility of chemical control of disease-associated missplicing by manipulating the splicing environment composed of SRSFs and CLKs in target cells. The gene discussed is ELP1; the disease is Fabry disease.